Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement in accordance with Section 130c Paragraph 1 SGB V between IKK classic and Abacus Medicine and Originalis B.V. to Bimzelx
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Conclusion of a non-exclusive discount agreement in accordance with Section 130c Paragraph 1 SGB V between IKK classic and Abacus Medicine and Originalis B.V. for Bimzelx (active ingredient: Bimekizumab, ATC code: L04AC21, contract period: October 1st, 2026-September 30th, 2028)
Related Procurement Opportunities
Similar tenders in Healthcare and Medicine, Pharmaceuticals